Robert B. Ford - 25 Aug 2022 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
CHAIRMAN AND CEO, Director
Signature
/s/ Robert B. Ford by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
25 Aug 2022
Net transactions value
-$6,643,284
Form type
4
Filing time
26 Aug 2022, 17:49:20 UTC
Previous filing
01 Apr 2022
Next filing
22 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $1,779,647 +45,492 +32% $39.12 187,563 25 Aug 2022 Direct
transaction ABT Common shares without par value Options Exercise $2,342,224 +56,933 +30% $41.14 244,496 25 Aug 2022 Direct
transaction ABT Common shares without par value Sale $10,765,154 -102,425 -42% $105.10 142,071 25 Aug 2022 Direct F1
holding ABT Common shares without par value 197,403 25 Aug 2022 Ford Family Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -45,492 -100% $0.000000* 0 25 Aug 2022 Common Shares 45,492 $39.12 Direct F3
transaction ABT Option (right to buy) Options Exercise $0 -56,933 -100% $0.000000* 0 25 Aug 2022 Common Shares 56,933 $41.14 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.60 to $105.43, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.
F3 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).